Abstract
In this issue of Blood, Cho et al demonstrate that blocking adenosine 5′-diphosphate (ADP) signaling to the P2Y12 receptor on platelets reduces the growth of ovarian cancer cells, implicating the P2Y12 inhibitor ticagrelor as a potential therapeutic option for primary and secondary prevention of ovarian cancer.1
Original language | English (US) |
---|---|
Pages (from-to) | 1177-1178 |
Number of pages | 2 |
Journal | Blood |
Volume | 130 |
Issue number | 10 |
DOIs |
|
State | Published - Sep 7 2017 |
ASJC Scopus subject areas
- Biochemistry
- Immunology
- Hematology
- Cell Biology